WallStreetZenWallStreetZen

NASDAQ: XLO
Xilio Therapeutics Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Be the first to know when Wall Street analysts revise their XLO stock forecasts and price targets.

Forecast return on equity

Is XLO forecast to generate an efficient return?

Company
-135.51%
Industry
146.59%
Market
89.5%
XLO's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is XLO forecast to generate an efficient return on assets?

Company
-13.98%
Industry
39.01%
XLO is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

XLO earnings per share forecast

What is XLO's earnings per share in the next 3 years based on estimates from 1 analyst?

Avg 1 year Forecast
-$0.61
Avg 2 year Forecast
-$0.80
Avg 3 year Forecast
-$0.41

XLO revenue forecast

What is XLO's revenue in the next 3 years based on estimates from 1 analyst?

Avg 1 year Forecast
$69.5M+649.41%
Avg 2 year Forecast
$85.0M+816.54%
Avg 3 year Forecast
$40.0M+331.31%
XLO's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

XLO revenue growth forecast

How is XLO forecast to perform vs Biotechnology companies and vs the US market?

Company
75.45%
Industry
57.7%
Market
9.75%
XLO's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
XLO's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

XLO vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
XLO$0.90N/AN/A
QNCX$1.02$7.67+651.67%Strong Buy
CNTB$0.85$8.00+842.29%Buy
CAMP$2.23N/AN/A
NRXP$2.78$28.50+925.18%Strong Buy
View Top Biotech Stocks

Xilio Therapeutics Stock Forecast FAQ

What is XLO's earnings growth forecast for 2025-2027?

(NASDAQ: XLO) Xilio Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 10.63%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 15.45%.

Xilio Therapeutics's earnings in 2025 is -$54,303,000.On average, 1 Wall Street analyst forecast XLO's earnings for 2025 to be -$31,587,187, with the lowest XLO earnings forecast at -$31,587,187, and the highest XLO earnings forecast at -$31,587,187. On average, 1 Wall Street analyst forecast XLO's earnings for 2026 to be -$41,425,818, with the lowest XLO earnings forecast at -$41,425,818, and the highest XLO earnings forecast at -$41,425,818.

In 2027, XLO is forecast to generate -$21,230,732 in earnings, with the lowest earnings forecast at -$21,230,732 and the highest earnings forecast at -$21,230,732.

If you're new to stock investing, here's how to buy Xilio Therapeutics stock.

What is XLO's revenue growth forecast for 2025-2027?

(NASDAQ: XLO) Xilio Therapeutics's forecast annual revenue growth rate of 75.45% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 57.7%, and it is also forecast to beat the US market's average forecast revenue growth rate of 9.75%.

Xilio Therapeutics's revenue in 2025 is $9,274,000.On average, 1 Wall Street analysts forecast XLO's revenue for 2025 to be $3,598,867,974, with the lowest XLO revenue forecast at $3,598,867,974, and the highest XLO revenue forecast at $3,598,867,974. On average, 1 Wall Street analysts forecast XLO's revenue for 2026 to be $4,401,493,205, with the lowest XLO revenue forecast at $4,401,493,205, and the highest XLO revenue forecast at $4,401,493,205.

In 2027, XLO is forecast to generate $2,071,290,920 in revenue, with the lowest revenue forecast at $2,071,290,920 and the highest revenue forecast at $2,071,290,920.

What is XLO's forecast return on assets (ROA) for 2025-2028?

(NASDAQ: XLO) forecast ROA is -13.98%, which is lower than the forecast US Biotechnology industry average of 39.01%.

What is XLO's Earnings Per Share (EPS) forecast for 2025-2027?

(NASDAQ: XLO) Xilio Therapeutics's current Earnings Per Share (EPS) is -$0.82. On average, analysts forecast that XLO's EPS will be -$0.61 for 2025, with the lowest EPS forecast at -$0.61, and the highest EPS forecast at -$0.61. On average, analysts forecast that XLO's EPS will be -$0.80 for 2026, with the lowest EPS forecast at -$0.80, and the highest EPS forecast at -$0.80. In 2027, XLO's EPS is forecast to hit -$0.41 (min: -$0.41, max: -$0.41).

What is XLO's forecast return on equity (ROE) for 2025-2028?

(NASDAQ: XLO) forecast ROE is -135.51%, which is considered weak.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.